Industry Expertise (3)
Laboratory Services
Biotechnology
Research
Areas of Expertise (3)
Drug Development
Computational Drug Re-Profiling
Drug Mechanism of Action
Links (1)
Sample Talks (1)
Opportunities for Drug Re-Profiling in Spinal Cord Injury
Every year over 100,000 people world wide survive a traumatic spinal cord injury (SCI) but will require daily, life-long assistance. In Canada, over 30,000 people live with SCI at an annual cost of 1.5B. SCI is a complicated process involving interlinked events, such as activation of the immune system, apoptosis and excito-toxic damage. Individually, each of these events can be reversed by identifying and then disrupting the networks of interacting proteins that mediate the associated processes. Unfortunately, sequence-based high throughput approaches to identify small molecule inhibitors have had limited success. By contrast, the competing approach to re-profile existing drugs is gaining more popularity. The talk discusses approaches for drug re-profiling in spinal cord injury from the perspective of the lessons learned from recent developments in poly-target pharmacology.
Availability
- Author Appearance
